tiprankstipranks
Trending News
More News >
Niagen Bioscience (NAGE)
NASDAQ:NAGE
US Market

Niagen Bioscience (NAGE) Earnings Dates, Call Summary & Reports

Compare
527 Followers

Earnings Data

Report Date
Aug 06, 2025
TBA Not Confirmed
Period Ending
2025 (Q2)
Consensus EPS Forecast
0.02
Last Year’s EPS
0
Same Quarter Last Year
Based on 3 Analysts Ratings

Earnings Call Summary

Earnings Call Date:May 07, 2025
|
% Change Since: 64.26%
|
Next Earnings Date:Aug 06, 2025
Earnings Call Sentiment|Positive
Niagen Biosciences had a strong start to 2025 with significant revenue growth and net income achievement. The company saw impressive growth in e-commerce and ingredients, expanded its Niagen Plus availability, and improved gross margins. However, challenges persist with regulatory issues around NMN and misconceptions about NAD supplements. Additionally, there could be delays in obtaining study results for Parkinson's treatment. Overall, the positive achievements outweigh the challenges.
Company Guidance
During the Niagen Biosciences' first quarter earnings call for fiscal 2025, several key financial metrics and strategic updates were highlighted. The company reported a revenue of $30.5 million, marking a 38% year-over-year increase, and a net income of $5.1 million. Cash generated from operations reached $7.9 million, with an ending cash balance of $55.6 million and no debt. The e-commerce sector was a significant driver of growth, contributing $16.8 million in net sales, a 31% increase from the previous year. The Niagen ingredient business also saw substantial growth, with sales reaching $8 million, a 95% year-over-year increase. Gross margin improved to 63.4%, up from 60.7% the previous year. The company's strategic initiatives include expanding the availability of Niagen Plus, now offered in nearly 600 clinics, and advancing research and regulatory engagements for pharmaceutical applications of NR (nicotinamide riboside), particularly in Parkinson's disease and ataxia-telangiectasia. The company also raised its full-year revenue growth outlook to 20%-25% year-over-year, reflecting confidence in the expanding NAD market.
Strong Revenue Growth
Niagen Biosciences reported $30.5 million in revenue for Q1 2025, marking a 38% year-over-year increase.
Net Income Achievement
The company achieved a net income of $5.1 million, a significant improvement from a net loss of $0.5 million in the previous year.
E-commerce and Ingredient Growth
E-commerce sales grew by 31% year-over-year, while the Niagen ingredient business saw a 95% increase.
Expansion of Niagen Plus
Niagen Plus is now available in nearly 600 clinics nationwide, with plans to expand to 1,000 by year-end.
Patent Portfolio Expansion
A new composition of matter patent was granted, expanding protection for all salt forms of nicotinamide riboside.
Improved Gross Margin
Gross margin improved to 63.4%, up from 60.7% the previous year.
Increased Cash Flow
Net cash provided by operations was $7.9 million, compared to $300,000 in the same period last year.
Raised Full-Year Revenue Outlook
The full-year top-line growth outlook was raised to 20% to 25% year-over-year.

Niagen Bioscience (NAGE) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

NAGE Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Aug 06, 2025
2025 (Q2)
0.01 / -
0
May 07, 2025
2025 (Q1)
0.02 / 0.07
-0.01830.00% (+0.08)
Mar 04, 2025
2024 (Q4)
0.02 / 0.09
0
Oct 31, 2024
2024 (Q3)
<0.01 / 0.03
0.005480.00% (+0.02)
Aug 07, 2024
2024 (Q2)
-0.02 / 0.00
-0.03
May 08, 2024
2024 (Q1)
-0.02 / -0.01
-0.0366.67% (+0.02)
Mar 06, 2024
2023 (Q4)
-0.03 / 0.00
-0.02
Nov 08, 2023
2023 (Q3)
-0.03 / <0.01
-0.01150.00% (+0.01)
Aug 09, 2023
2023 (Q2)
-0.04 / -0.03
-0.0966.67% (+0.06)
May 10, 2023
2023 (Q1)
-0.05 / -0.03
-0.1172.73% (+0.08)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

NAGE Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
May 07, 2025
$8.45$9.24+9.35%
Mar 04, 2025
$5.60$8.55+52.68%
Oct 31, 2024
$3.49$5.86+67.91%
Aug 07, 2024
$2.63$2.88+9.51%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Niagen Bioscience (NAGE) report earnings?
Niagen Bioscience (NAGE) is schdueled to report earning on Aug 06, 2025, TBA Not Confirmed.
    What is Niagen Bioscience (NAGE) earnings time?
    Niagen Bioscience (NAGE) earnings time is at Aug 06, 2025, TBA Not Confirmed.
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is NAGE EPS forecast?
          NAGE EPS forecast for the fiscal quarter 2025 (Q2) is 0.02.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis